TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from IO Biotech ( (IOBT) ).
On November 17, 2025, IO Biotech, Inc. announced the resignation of Brian Burkavage from his role as Senior Vice President and Chief Accounting Officer, effective December 12, 2025. His departure is amicable and due to his pursuit of another opportunity. Following his resignation, Amy Sullivan, the current Chief Financial Officer, will assume the role of principal accounting officer. No new compensation arrangements will be made for Ms. Sullivan in her new role.
The most recent analyst rating on (IOBT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.
Spark’s Take on IOBT Stock
According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.
IO Biotech faces significant challenges due to its financial instability and lack of revenue. However, the progress in clinical trials and secured financing improve its future prospects, though it remains speculative. The technical analysis suggests neutral momentum, and the valuation highlights typical risks associated with biotech stocks awaiting commercialization.
To see Spark’s full report on IOBT stock, click here.
More about IO Biotech
Average Trading Volume: 3,734,677
Technical Sentiment Signal: Sell
Current Market Cap: $54.08M
For detailed information about IOBT stock, go to TipRanks’ Stock Analysis page.